Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors - Related Studies

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

This study is ongoing, but not recruiting participants.

Study NCT00004095. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Bladder Cancer
		Breast Cancer
		Colorectal Cancer
		Kidney Cancer
		Lung Cancer
		Pancreatic Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms
		Carcinoma, Renal Cell
		Colorectal Neoplasms
		Kidney Neoplasms
		Lung Neoplasms
		Pancreatic Neoplasms
		Urinary Bladder Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Breast Diseases
		Carcinoma
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Kidney Diseases
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Pancreatic Diseases
		Rectal Diseases
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Skin Diseases
		Thoracic Neoplasms
		Urinary Bladder Diseases
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		gemcitabine hydrochloride
		irinotecan hydrochloride

5	Additional drug interventions recognized in this trial
		Camptothecin
		Gemcitabine
		Irinotecan

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Robert H. Lurie Cancer Center
		National Cancer Institute (NCI)